| 1. | cyberspacer | |
| 2. | snezhinka4 | |
| 3. | craymonk | |
| 4. | captureME | |
| 5. | robindo |
Top Board Researchers
These are the top researchers based on quality of posts as voted by board members. Typically they know their stuff and are a great
way to catch up on what the company is all about.
HOW DO I BECOME ONE?
Just do great research! As other members approve of your posts, you earn points that move you up the ranks.| 1. | craymonk 01/31/2018 Started a nice position today. |
| 2. | robindo 03/26/2018 Canaccord Genuity resumes coverage as a buy, $210PT |
| 3. | cyberspacer 01/31/2018 BIG news out!!! - Announces SAGE-217 meets primary endpoint; co expects to initiate clinical development of SAGE-217 in disord… |
| 4. | cyberspacer 12/08/2017 MC is $6.4 bil |
| 5. | cyberspacer 02/07/2018 Receives FDA Breakthrough Therapy Designation for SAGE-217 for the Treatment of Major Depressive Disorder |
| 6. | captureME 02/07/2018 Commences $575 mln common stock offering |
| 7. | snezhinka4 04/10/2018 Deal rumors swirling following headlines that the company has cancelled out of an upcoming conference presen… |
| 8. | craymonk 12/08/2017 Wow, out of the loop |
| 9. | captureME 12/07/2017 This Biotech Catapults 70% Higher On Depression Drug Results |
NEW since the last time you visited this board.
Currently a TOP 10 POST for this board.
Currently a TOP 5 RESEARCHER for this board.
Specific post has replies to it.
A Researcher you are currently FOLLOWING
Other Researchers rate this post HIGH
Other Researchers rate this post LOW
Sage Therapeutics, Inc.
- SAGE
- Public Stock Message Board
Filtering by:
-
To use your chart in a post, click the
icon above the chart. From there you can get the chart link or download the image.